$2.64
-0.93 (-26.05%)
Open$3.33
Previous Close$3.57
Day High$3.33
Day Low$2.35
52W High$24.00
52W Low$1.79
Volume—
Avg Volume1.46M
Market Cap18.25M
P/E Ratio—
EPS$-25.49
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+863.3% upside
Current
$2.64
$2.64
Target
$25.43
$25.43
$14.54
$25.43 avg
$32.33
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.53M | 2.25M | 2.34M |
| Net Income | -604,093 | -536,841 | -566,432 |
| Profit Margin | -23.9% | -23.9% | -24.2% |
| EBITDA | -828,287 | -680,626 | -721,197 |
| Free Cash Flow | -326,986 | -310,260 | -424,378 |
| Rev Growth | -6.1% | -2.1% | -7.6% |
| Debt/Equity | 0.51 | 0.64 | 0.68 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |